Cure Forward
Cure Forward is a Boston-based private company founded in 2014 that helps cancer patients and physicians access advanced oncology treatments, having raised approximately $27.8M across four funding rounds led by Apple Tree Partners between 2015 and 2017.
- Company typePrivate
- Founded2014
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What Cure Forward does
Cure Forward was a Boston-based, for-profit private company founded in 2014 that operated in the oncology patient-access space. Per its firmographic short description, the company helped cancer patients and physicians access advanced treatments in oncology — functionally a service connecting patients and providers to oncology clinical-trial and treatment pathways. Detailed product architecture, technology stack, integration points, and revenue mechanics are not documented in the available inputs; no specific products, APIs, SDKs, or platform modules are enumerated across the sourced material.
The company was capitalized through approximately $27.8M across four funding events between 2015 and 2017. The largest single event was a $15,000,000 round on 2015-06-18 led by Apple Tree Partners, a healthcare-specialist investor, with three subsequent financings of roughly $4M–$4.5M each through May 2017. The leadership team — CEO Frank Ingari, CFO Sean Bridgeo, and CMO Stacey Santo — was assembled during the growth phase, but no subsequent hires, partnerships, product launches, customer wins, or M&A activity are documented after May 2017.
The most operationally significant present-day signal is that CureForward.com is listed for sale on HugeDomains at $19,195 ($799.79/month for 24 months). This is an anomalous fact: the active listing of a company's primary domain on a domain marketplace is consistent with a wind-down, divestiture, or — at minimum — abandonment of the digital surface. The source explicitly notes this does not conclusively prove the entity has ceased operations, but in the absence of any other operating evidence for ~7+ years, this is the dominant signal in the dataset.
Cure Forward firmographics
Firmographics- Name
- Cure Forward
- Website
- https://cureforward.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cure Forward is a Boston-based private company founded in 2014 that helps cancer patients and physicians access advanced oncology treatments, having raised approximately $27.8M across four funding rounds led by Apple Tree Partners between 2015 and 2017.
- Ownership category
- akta.pro rank
Cure Forward industry classification
Industry- Product category
- Oncology Patient Treatment Access
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)
- akta.pro secondary industry
- Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD)
Keywords
Where Cure Forward is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Markets served
Cure Forward business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Cure Forward product offering
Product offeringCore offering
Cure Forward operates a platform that connects cancer patients and their physicians with advanced oncology treatments. The service facilitates access to precision oncology options, including clinical trials and emerging therapies, by linking patients to relevant treatment opportunities beyond standard care.
Product overview
No product or service information is available. The source data indicates CureForward.com is a domain name listed for sale on HugeDomains.com for $19,195. No information about Cure Forward's actual products, services, or business offerings is present in the provided source material.
Differentiator
Problem solved
Functional benefit
Products and services
- Oncology Treatment Access Platform
Companies that use Cure Forward
Customer profileIdeal customer profiles2 records
Cure Forward technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cure Forward partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights3 records
Cure Forward competitors and assessment
Company assessmentDirect peers
- Massive Bio: AI-driven oncology clinical trial matching platform connecting cancer patients with appropriate trials. Directly comparable to Cure Forward's oncology-treatment-access mission and similar target user (oncology patients + referring physicians).
- Antidote: Digital clinical trial matching and patient-recruitment company that built a precision-medicine patient-finding engine for pharma sponsors. Overlaps with Cure Forward's use of clinical data to connect patients with advanced treatments.
- Navigating Cancer: Patient engagement and care management platform purpose-built for oncology, including symptom management and clinical trial awareness. Closely adjacent to Cure Forward's oncology patient-navigation focus.
- Trial Library: Clinical trial matching with an emphasis on ensuring diverse patient enrollment. Operates in the same patient-to-trial matching category as Cure Forward and serves similar pharma sponsor and patient users.
- Clara Health: Patient-first clinical trial matching platform focused on reducing barriers to trial enrollment. Directly comparable as a digital health intermediary that helps patients access advanced therapies, including oncology.
- Deep 6 AI: AI platform that mines clinical records to match patients to trials and accelerate study recruitment. Strong direct peer — both companies use data-driven matching to route patients toward advanced oncology and specialty treatments.
- Mendel.ai: AI-powered oncology clinical trial matching and patient cohort identification, focused on oncology and rare diseases. Directly overlaps with Cure Forward's cancer-treatment-access proposition.
Broad incumbents
- Tempus Labs: AI-powered precision medicine platform with extensive oncology data, sequencing, and clinical-trial matching capabilities. Much larger incumbent operating across the same oncology-treatment-access value chain.
- Flatiron Health: Roche-owned oncology-specific EHR and real-world data platform connecting providers, patients, and pharma researchers. A broad oncology platform incumbent whose treatment-access and trial-recruitment capabilities overlap with Cure Forward's mission at much larger scale.
Emerging players
- Outcomes4Me: Direct-to-patient oncology app that combines treatment options, clinical trial matching, and care navigation for cancer patients. Overlaps meaningfully with Cure Forward's patient-side treatment-access offerings.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Cure Forward social profiles
Digital presenceCure Forward financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cure Forward leadership team
Management profileNumber of profiles
Profiles3 records
Cure Forward funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cure Forward M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cure Forward
What does Cure Forward do?
Cure Forward operates a platform that connects cancer patients and their physicians with advanced oncology treatments. The service facilitates access to precision oncology options, including clinical trials and emerging therapies, by linking patients to relevant treatment opportunities beyond standard care.
When was Cure Forward founded?
Cure Forward was founded in 2014. It employs 11 to 50 people.
Where is Cure Forward based?
Cure Forward is headquartered in Boston, United States, in the North America region.
Who are Cure Forward's main competitors?
Direct peers on record are Massive Bio, Antidote, Navigating Cancer, Trial Library, Clara Health, Deep 6 AI and Mendel.ai. Broad incumbents are Tempus Labs and Flatiron Health. Outcomes4Me is listed as an emerging player.
Does Cure Forward have an API?
No public API is recorded for Cure Forward.
What industry is Cure Forward in?
Cure Forward's product category is Oncology Patient Treatment Access. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLALAFAD, Oncology Remote Symptom Monitoring & Care Navigation. Its SIC code is 8000.